# Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

> **NCT01011933** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma

## Interventions

- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01011933
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011933, "Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01011933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*